Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Earnings
  • News

4D Molecular Therapeutics Cash And Cash Equivalents And Marketable Securities Were $218.5M As Of December 31, 2022, As Compared To $315.4M As Of December 31, 2021

By Happy Mohamed
Today, 6:33 PM
Full Year 2022 Financial Results Cash and Cash Equivalents and Marketable Securities: Cash and cash equivalents and marketable securities were $218.5 million as of December 31, 2022, as compared

FDMT

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

4D Molecular Discloses Updated Data From Currently Paused Fabry Disease Cardiomyopathy Study

By Vandana Singh
Today, 6:33 PM
4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced updated interim safety and efficacy data from the two 4D-310 INGLAXA Phase 1/2 trials for…

FDMT

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

SVB Leerink Maintains Market Perform on 4D Molecular Therapeutics, Lowers Price Target to $14

By Benzinga Newsdesk
Today, 6:33 PM
SVB Leerink analyst Mani Foroohar maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Market Perform and lowers the price target from $15 to $14.

FDMT

Read More
1 minute read
  • Analyst Ratings

Analyst Ratings for 4D Molecular Therapeutics

By Benzinga Insights
Today, 6:33 PM
Within the last quarter, 4D Molecular Therapeutics (NASDAQ:FDMT) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

FDMT

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • Price Target
  • Small Cap

BMO Capital Markets Says 4D Molecular Could Be ‘Attractive Acquisition Target’

By Vandana Singh
Today, 6:33 PM
BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with an Outperform rating and a price target of $50. The…

FDMT

Read More
8 minute read
  • Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights
Today, 6:33 PM
  During Thursday's session, 108 stocks hit new 52-week highs.

ABC

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

By Lisa Levin
Today, 6:33 PM
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.

A

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Initiation
  • News
  • Price Target
  • Small Cap

HC Wainwright Creates Bullish Pitch On 4D Molecular Citing ‘Broader Systemic Potential’

By Vandana Singh
Today, 6:33 PM
HC Wainwright has initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with a price target of $36 and a Buy rating. The…

FDMT

Read More
6 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For November 18, 2022

By Benzinga Insights
Today, 6:33 PM
Upgrades

ABBV

Read More
1 minute read
  • Long Ideas
  • Markets
  • Media
  • News
  • Small Cap
  • Top Stories
  • Trading Ideas

Cramer On This Stock Down 65% Year-To-Date: ‘I Do Believe It’s Bottoming, But I Don’t Know What Gets It Higher’

By Lisa Levin
Today, 6:33 PM
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."

BTAI

Posts navigation

1 2 … 8 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service